Alnylam Pharmaceuticals Inc. settled a trade secrets suit brought by partner Arbutus Biopharma Corp. and inked a new licensing agreement that restructures their relationship. The twin actions free Alnylam from a thorny legal problem and enable it to manufacture its own drug candidates.
Under the new agreement Alnylam will make a one-time payment of $30 million to Tekmira to buy out manufacturing obligations so Alnylam can independently manufacture lipid nanoparticle (LNP) technology for RNA interference (RNAi) therapeutics
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?